查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1375994

異位性皮膚炎治療藥物的市場規模、佔有率和趨勢分析報告：按藥物類別、給藥途徑、地區和細分市場預測，2023-2030年

Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Route Of Administration, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

異位性皮膚炎治療藥物市場成長與趨勢：

Grand View Research, Inc.的最新報告顯示，到2030年，全球異位性皮膚炎治療市場規模預計將達到276.8億美元。

預計2023年至2030年年複合成長率為8.4%。由於全球異位性皮膚炎盛行率不斷上升、認知不斷提高以及對治療的高需求等因素，異位性皮膚炎 (AD) 治療市場有望迎來成長機會。此外，不斷推出創新產品來佔領市場，是廠商贏得市場佔有率、保持主導地位的關鍵策略。

越來越多的高效且副作用較少的產品正在研發中，預計將推動市場的發展。例如，預計2020年至2029年間將有11種治療異位性皮膚炎的新藥上市。其中包括以下藥物類別：Janus 激酶 (JAK) 抑制劑、磷酸二酯酶-4 (PDE-4) 和白介素-4&-13 (IL-4/13)。這些新藥的上市將改善生活品質，為重度和中度AD患者提供治療選擇。

快速通道指定等法規支持預計將加速 AD 的研究和開發。例如，Demira 的 lebrikizumab 獲得了快速通道指定。此外，2020年10月，Forte Biosciences, Inc.的藥物FB-401獲得FDA的快速通道指定。因此，公司對研發的興趣增加預計將推動市場成長。

增加資金和積極主動的政府配合措施來研究和開發異位性皮膚炎新治療方法將支持該地區的成長。公共和私人組織之間的合作預計將提高世界各地消費者的意識。例如，2022年6月，大塚製藥株式會社（大塚控股株式會社）宣佈在日本上市AD治療藥物Moiselt軟膏（difamilast）。該藥是一種非類固醇外用磷酸二酯酶 4 型抑制劑。

在日本，日本皮膚病學會 (JDA) 制定了 AD 指南。該指南於2020年進行了修訂，不僅規定了診斷標準，還規定了治療方法。例如，用局部皮質類固醇和他克莫司治療發炎相關的AD。這有利於患者的系統性治療並提高治療效果。

特應性皮膚炎治療藥物市場亮點

  • 生物製藥生物製藥核准數量增加，2022年異位性皮膚炎治療藥物市場以生物製劑為主。
  • 注射給藥途徑將在 2022 年佔據最大佔有率，並預計在整個預測期內保持其主導地位。
  • 由於領先企業的存在、異位性皮膚炎盛行率的增加以及該地區研究活動的活性化，北美在 2022 年佔據了市場主導地位。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 異位性皮膚炎治療藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 異位性皮膚炎治療藥物市場的分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 異位性皮膚炎治療藥物：按藥物類別估計和趨勢分析

  • 異位性皮膚炎治療藥物市場：要點
  • 異位性皮膚炎治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 皮質類固醇
    • 2018年至2030年皮質類固醇市場估計與預測
  • 鈣調磷酸酶抑制劑
    • 2018年至2030年鈣調神經磷酸酶抑制劑市場估計與預測
  • PDE4抑制劑
    • 2018年至2030年PDE4抑制劑市場預測
  • 生技藥品
    • 2018年至2030年生技藥品市場估計與預測
  • 其他
    • 2018 年至 2030 年其他市場估計與預測

第5章 異位性皮膚炎治療藥物：按給藥途徑的估計和趨勢分析

  • 異位性皮膚炎治療藥物市場：要點
  • 異位性皮膚炎治療藥物市場：2022 年和 2030 年趨勢和市場佔有率分析
  • 外用製劑
  • 注射藥物
  • 口腔醫學

第6章 異位性皮膚炎治療藥物市場：區域估計和趨勢分析

  • 區域展望
  • 按地區分類的異位性皮膚炎治療藥物市場：關鍵市場點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • Pfizer Inc.
    • Sanofi
    • Regeneron Pharmaceuticals Inc.
    • LEO Pharma Inc
    • Otsuka Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • GALDERMA LABORATORIES, LP
    • Dermira, Inc. (Eli Lilly and Company)
    • Novartis AG
    • Incyte Corporation
Product Code: GVR-2-68038-546-5

Atopic Dermatitis Drugs Market Growth & Trends:

The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030, according to a new report by Grand View Research, Inc.. It is expected to expand at a CAGR of 8.4% from 2023 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.'s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights:

  • In 2022, biologics dominated the market owing to their higher demand and rising biologics approvals
  • The injectable route of administration segment held the largest share in 2022 and is likely to maintain its dominance throughout the forecast period
  • North America dominated the market in 2022 due to the presence of leading market players, increased prevalence of atopic dermatitis, and increased research activities within the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Drug Class
    • 1.1.2. Route of Administration
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Atopic Dermatitis Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. Atopic Dermatitis Drugs: Drug Class Estimates & Trend Analysis

  • 4.1. Atopic Dermatitis Drugs Market: Key Takeaways
  • 4.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Corticosteroids
    • 4.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Calcineurin Inhibitors
    • 4.4.1. Calcineurin inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. PDE4 Inhibitors
    • 4.5.1. PDE4 Inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Biologics
    • 4.6.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs: Route of Administration Estimates & Trend Analysis

  • 5.1. Atopic Dermatitis Drugs Market: Key Takeaways
  • 5.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Topical
    • 5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Injectable
    • 5.4.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Oral
    • 5.5.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Atopic Dermatitis Drugs Market by Region: Key Marketplace Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Pfizer Inc.
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Sanofi
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Regeneron Pharmaceuticals Inc.
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. LEO Pharma Inc
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. Otsuka Pharmaceutical Co., Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. AbbVie Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. GALDERMA LABORATORIES, L.P.
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Dermira, Inc. (Eli Lilly and Company)
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Novartis AG
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. Incyte Corporation
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 3 North America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 4 North America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 6 U.S. atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7 Canada atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 Canada atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 Europe atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 10 Europe atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Europe atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Germany atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 UK atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 15 UK atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 France atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 17 France atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Italy atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 19 Italy atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20 Spain atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Spain atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Sweden atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 23 Sweden atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Norway atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 25 Norway atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 26 Denmark atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 Denmark atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 32 China atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Japan atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Japan atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 India atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 India atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Thailand atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Thailand atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 South Korea atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 40 South Korea atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Latin America atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Latin America atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Latin America atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 44 Brazil atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 45 Brazil atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 Mexico atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 47 Mexico atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Argentina atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 Argentina atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 Middle East and Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 51 Middle East and Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa atopic dermatitis drugs market, by region, 2018 - 2030 (USD Million)
  • Table 53 South Africa atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 54 South Africa atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 56 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 UAE atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 UAE atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Kuwait atopic dermatitis drugs market, by drug class, 2018 - 2030 (USD Million)
  • Table 60 Kuwait atopic dermatitis drugs market, by route of administration, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Atopic dermatitis drugs: Market outlook
  • Fig. 9 Atopic dermatitis drugs: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Atopic dermatitis drugs market driver impact
  • Fig. 15 Atopic dermatitis drugs market restraint impact
  • Fig. 16 Atopic dermatitis drugs market strategic initiatives analysis
  • Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
  • Fig. 18 Atopic dermatitis drugs market: Drug class outlook and key takeaways
  • Fig. 19 Corticosteroids market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Calcineurin inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 PDE4 inhibitors market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Atopic dermatitis drugs market: Route of administration movement analysis
  • Fig. 25 Atopic dermatitis drugs market: Route of administration outlook and key takeaways
  • Fig. 26 Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Global atopic dermatitis drugs market: Regional movement analysis
  • Fig. 30 Global atopic dermatitis drugs market: Regional outlook and key takeaways
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)